Viramal
1 known investors
Viramal is a specialist pharmaceutical company developing transdermal and vaginally applied prescription and non-prescription therapies for women's sexual and reproductive health, targeting conditions such as endometriosis, chronic pelvic pain, and menopause. It focuses on targeted, lower-dose drug delivery to the pelvic cavity across the female reproductive lifecycle.
Investors · 1
Companies House · registry record
View on Companies House ↗- Registered name
- VIRAMAL LIMITED
- Company number
- 08485006
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 12 Apr 2013
- Registered office
- 167-169 Great Portland Street, 5th Floor, London, W1W 5PF
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 28 Feb 2025 · next due 30 Nov 2026
- Confirmation statement
- last made up to 2 Mar 2026 · next due 16 Mar 2027
Current officers · 7
- Amba Secretaries Limited — corporate secretary, appointed 5 Oct 2021
- Oliver Stephen Bates — director, appointed 12 Apr 2013
- Simona Fiore — director, appointed 27 Mar 2020
- Enda Mcveigh — director, appointed 5 Oct 2021
- Anne Katrin Niederstaetter — director, appointed 21 Mar 2022
- Gurpartap Singh Sachdeva — director, appointed 1 Jul 2019
- James Nicholas Thorniley — director, appointed 1 Nov 2013
Source: Companies House public register · retrieved 16 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Viramal do?
- Viramal is a specialist pharmaceutical company developing transdermal and vaginally applied prescription and non-prescription therapies for women's sexual and reproductive health, targeting conditions such as endometriosis, chronic pelvic pain, and menopause. It focuses on targeted, lower-dose drug delivery to the pelvic cavity across the female reproductive lifecycle.
- Who are Viramal's investors?
- Viramal's investors include NCL Technology Ventures Ltd..